Gilenya: cardiac monitoring requirements strengthened

The cardiac monitoring requirements for patients with multiple sclerosis starting Gilenya (fingolimod) have been updated owing to cardiac concerns, including unexplained death in six patients.

Gilenya is a sphingosine 1-phosphate receptor modulator and is licensed for the treatment of multiple sclerosis
Gilenya is a sphingosine 1-phosphate receptor modulator and is licensed for the treatment of multiple sclerosis

The MHRA has issued the new advice for Gilenya to reduce the risk of transient bradycardia and heart block.

Updated advice

A 12-lead ECG reading should be taken before starting treatment and repeated with concurrent BP and heart rate monitoring for at least 6 hours after the first dose. If any clinically relevant cardiac effects are noted, monitoring should be continued until they are resolved. Relevant effects include new-onset second or third degree cardiac block or symptomatic bradycardia, heart rate less than 40bpm or persistent second degree AV block 6 hours after the initial dose, or a decrease in heart rate of more than 20bpm compared with baseline.

The increased monitoring requirements should be repeated if treatment is interrupted for more than 2 weeks.

More frequent LFTs

In addition, the manufacturer now also recommends more frequent monitoring of liver functioning, which should be performed at baseline, after 1, 3, 6, 9 and 12 months of treatment and periodically thereafter.

MHRA Drug Safety Update – February 2012

View Gilenya drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases